This is the authors' abstract. We don't add key points for this paper.
Cannabidiol (CBD), a nonpsychoactive marijuana constituent, was recently shown as an oral antihyperalgesic compound in a rat model of acute inflammation. We examined whether the CBD antihyperalgesic effect could be mediated by cannabinoid receptor type 1 (CB1) or cannabinoid receptor type 2 (CB2) and/or by transient receptor potential vanilloid type 1 (TRPV1). Rats received CBD (10 mg kg −1 ) and the selective antagonists: SR141716 ( N ‐(piperidin‐1‐yl)‐5‐(4‐chlorophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide) for CB1, SR144528 ( N ‐[(1 S )‐endo‐1,3,3‐trimethylbicyclo[2.2.1]heptan‐2‐yl]‐5‐(4‐chloro‐3‐methylphenyl)‐1‐(4‐methylbenzyl)pyrazole‐3 carboxamide) for CB2 and capsazepine (CPZ) for TRPV1 receptors. The intraplantar injection of carrageenan in rats induced a time‐dependent thermal hyperalgesia, which peaked at 3 h and decreased at the following times. CBD, administered 2 h after carrageenan, abolished the hyperalgesia to the thermal stimulus evaluated by plantar test. Neither SR141716 (0.5 mg kg −1 ) nor SR144528 (3 and 10 mg kg −1 ) modified the CBD‐induced antihyperalgesia; CPZ partially at the lowest dose (2 mg kg −1 ) and fully at the highest dose (10 mg kg −1 ) reversed this effect. These results demonstrate that TRPV1 receptor could be a molecular target of the CBD antihyperalgesic action. British Journal of Pharmacology (2004) 143 , 247–250. doi: 10.1038/sj.bjp.0705920
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: